Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician’s perspective-Reference-Cited by-同舟云学术

Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician’s perspective

Published:2020-06 Issue:9 Volume:15 Page:779-799
ISSN:1746-0913
Container-title:Future Microbiology
language:en
Short-container-title:Future Microbiology

Author:

Guglielmetti Lorenzo¹²³^ORCID,Chiesi Sheila⁴⁵,Eimer Johannes⁶,Dominguez Jose⁷,Masini Tiziana⁸,Varaine Francis³,Veziris Nicolas²⁹,Ader Florence¹⁰¹¹,Robert Jérôme¹²

Affiliation:

1. APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, F-75013 Paris, France

2. Sorbonne Université, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 2, F-75013, Paris, France

3. Médecins Sans Frontières, France

4. Department of Infectious Diseases, ‘GB Rossi’ Hospital, Verona, Italy

5. University of Verona, Verona, Italy

6. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden

7. Research Institute Germans Trias i Pujol, CIBER Respiratory Diseases, Universitat Autònoma de Barcelona, Badalona, Spain

8. Independent Consultant, Italy

9. APHP, Département de Bactériologie, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (CNR-MyRMA), Hôpitaux Universitaires de l’Est Parisien, F-75012, Paris, France

10. Département des Maladies infectieuses et tropicales, Hospices Civils de Lyon, F-69004, Lyon, France

11. Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Univ Lyon, F-69007 Lyon, France

Abstract

Drug-resistant tuberculosis (TB) represents a substantial threat to the global efforts to control this disease. After decades of stagnation, the treatment of drug-resistant TB is undergoing major changes: two drugs with a new mechanism of action, bedaquiline and delamanid, have been approved by stringent regulatory authorities and are recommended by the WHO. This narrative review summarizes the evidence, originating from both observational studies and clinical trials, which is available to support the use of these drugs, with a focus on special populations. Areas of uncertainty, including the use of the two drugs together or for prolonged duration, are discussed. Ongoing clinical trials are aiming to optimize the use of bedaquiline and delamanid to shorten the treatment of drug-resistant TB.

Publisher

Future Medicine Ltd

Subject

Microbiology (medical),Microbiology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fmb-2019-0309

Reference143 articles.

1. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva World Health Organ. Licence: CC BY-NC-SA 3.0 IGO (2019).

2. FDA. Drug approval package: pretomanid. https://wwwaccessdatafdagovdrugsatfdadocsnda2019212862Orig1s000TOCcfm

3. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thiadiazole-thiazole derivatives as potent anti-tubercular agents: Synthesis, biological evaluation, and In silico docking studies;European Journal of Medicinal Chemistry Reports;2024-12

2. Photocatalytic Carbamoyl Radical Transfer to Alkenyl Azaarenes;Synlett;2024-01-29

3. Expanding the chemical space of ester of quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives as potential antitubercular agents;RSC Medicinal Chemistry;2024

4. Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India;Indian Journal of Tuberculosis;2023-12

5. Utility of Machine Learning and Radiomics Based on Cavity for Predicting the Therapeutic Response of MDR-TB;Infection and Drug Resistance;2023-10